For a number of years, numerous scoring systems have striven to have therapeutic efficacy assessed not only by the doctor but also by the patient. In an illness whose severity depends not on the characteristic features of the plaques but on their impact on the quality of life, the two form a particularly interesting complement to each other. The questionnaires are completed by the patients. They are of two main types, sometimes used in combination. Some of these questionnaires focus primarily on the symptoms of psoriasis, like the PSA, presented below. Others focus mainly on the quality of life or state of health, such as the DLQI and the SF-36, presented above, which are used to measure the severity of psoriasis’ impact on the quality of life, and may be repeated throughout the therapeutic trials.

SPIN Presentation


Follow us

The other websites of the foundation